![Christopher L. Brooks](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Christopher L. Brooks
No más puestos en curso
Historial de carrera de Christopher L. Brooks
Antiguos cargos conocidos de Christopher L. Brooks.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
STEMLINE THERAPEUTICS, INC. | Corporate Officer/Principal | 01/01/2010 | - |
Formación de Christopher L. Brooks.
State University of New York at Binghamton | Undergraduate Degree |
The Trustees of Columbia University in The City of New York | Doctorate Degree |
Estadísticas
Internacional
Estados Unidos | 4 |
Operativa
Corporate Officer/Principal | 1 |
Undergraduate Degree | 1 |
Doctorate Degree | 1 |
Sectorial
Consumer Services | 3 |
Health Technology | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 1 |
---|---|
Stemline Therapeutics, Inc.
![]() Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY. | Health Technology |